Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.

ABSTRACT: Erdosteine is a drug approved for the treatment of acute and chronic pulmonary diseases, originally developed as a mucolytic agent. It belongs to the thiol-based family of drugs that are known to also possess potentially important antioxidant and anti-inflammatory properties, and exhibit antibacterial activity against a variety of medically important bacterial species. Erdosteine is a prodrug that is metabolized to the ring-opening compound metabolite M1 (MET 1), which has mucolytic properties. Experimental studies have documented that erdosteine prevents or reduces lung tissue damage induced by oxidative stress and, in particular, that Met 1 also regulates reactive oxygen species production. The RESTORE study, which has been the only trial that investigated the effects of a thiol-based dr

SUBMITTER: Cazzola M 

PROVIDER: S-EPMC7647991 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature